Table 1 Baseline characteristics
Characteristics | Training cohort | Validation cohort | p-value |
|---|---|---|---|
All | 135 (70.3) | 57 (29.7) | |
Gender | 0.083 | ||
Male | 110 (81.5) | 40 (70.2) | |
Female | 25 (18.5) | 17 (29.8) | |
Age (years) | 0.002 | ||
Mean | 62 | 66 | |
Range | 47–83 | 48–92 | |
Tumor location | 0.693 | ||
Cervical | 3 (2.2) | 3 (5.3) | |
Upper | 28 (20.7) | 10 (17.5) | |
Middle | 71 (52.6) | 28 (49.1) | |
Lower | 33 (24.4) | 16 (28.1) | |
Tumor length (cm3) | 0.414 | ||
≤5 | 75 (55.6) | 28 (49.1) | |
>5 | 60 (44.4) | 29 (50.9) | |
T stage | 0.335 | ||
T2 | 11 (8.1) | 1 (1.8) | |
T3 | 78 (57.8) | 38 (66.7) | |
T4a | 39 (28.9) | 16 (28.1) | |
T4b | 7 (5.2) | 2 (3.5) | |
N stage | 0.576 | ||
N0 | 5 (3.7) | 2 (3.5) | |
N1 | 52 (38.5) | 16 (28.1) | |
N2 | 62 (45.9) | 31 (54.4) | |
N3 | 16 (11.9) | 8 (14.0) | |
M stage | 0.015 | ||
M0 | 117 (86.7) | 41 (71.9) | |
M1 | 18 (13.3) | 16 (28.1) | |
cTNM stage | 0.112 | ||
II | 8 (5.9) | 3 (5.3) | |
III | 62 (45.9) | 22 (38.6) | |
IVA | 47 (34.8) | 16 (28.1) | |
IVB | 18 (13.3) | 16 (28.1) | |
Concurrent Chemotherapy | 0.122 | ||
Yes | 89 | 44 | |
No | 46 | 13 | |
Pre-NLR | 0.194 | ||
Mean ± SD | 2.67 ± 1.14 | 2.43 ± 1.15 | |
Range | 0.89–7.42 | 0.95–6.14 |